The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 1.19 — grey zone — between safe and distressedWatch
- Earnings-manipulation signal · Beneish M -3.12 — no flag raisedOK
- Earnings quality 92/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2025, as INTEGRA LIFESCIENCES HOLDINGS CORP reports it. History and quarterly detail are in the app.
- Codman Specialty Surgical$1.2B
- Tissue Technologies$434.7M
Leadership changes
From INTEGRA LIFESCIENCES HOLDINGS CORP's own filings, the day they're filed.
- Mojdeh Poul · Chief Executive Officer · departureeff. 2026-05-01
- Jan De Witte · President · appointmenteff. 2024-02-27
- Stuart M. Essig · Chairman · appointmenteff. 2024-02-27
Latest filings
- 8-K · Company announcement2026-05-08
- 10-Q · Quarterly report2026-05-05
- 8-K · Company announcement2026-05-05
- 8-K · Company announcement2026-05-05
- 8-K · Company announcement2026-04-15
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about INTEGRA LIFESCIENCES HOLDINGS CORP, every answer cited🔒
- The Intelligence Brief — added when INTEGRA LIFESCIENCES HOLDINGS CORP's brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.